1. The Latest Data on Oral Prostacyclin Therapy in PAH

3. Program Overview

4. Background

5. Case Study 1

6. Risk Assessment in PAH

7. Case Study 1 Diagnosis and Treatment Plan

8. Case Study 1: Ten Months Later

9. Guideline-Recommended Treatment Options for Patient on PDE5I Monotherapy

10. Case Study 1 on Dual Combination Therapy

11. Case Study 1: Three Years Post Diagnosis

12. Recommendations for Treatment Escalation in Patient on Background ERA + PDE5I

13. Case Study 1 Therapy Escalation

14. GRIPHON: Treatment Effect by Subgroup

15. Initial Treatment Decision

16. Low-Risk Criteria at Diagnosis and at First Reevaluation

17. Case Study 2

18. Diagnostic and Therapeutic Dilemmas in Complex Patients With Scleroderma

19. The Rationale for Combination Therapy

20. Recommendations for Initial Combination Therapy

21. French Registry: Survival Based on Number of Low-Risk Criteria Achieved at First Evaluation

22. Case Study 2: Two-Month Follow Up

23. Therapy Escalation: Treatment Decision

24. GRIPHON Study Design

25. Effect of Selexipag on Primary Composite Endpoint in GRIPHON

26. Concluding Remarks

27. Abbreviations

28. Abbreviations (cont)

29. Abbreviations (cont)